35 completed, 16 recruiting, 13 unknown, 8 active not recruiting. 45 Phase 2, 30 Phase 1, 15 Phase 3, 2 Phase 4, 1 Early Phase 1.
Follow Advanced Non-Small Cell Lung Cancer: new trials by email Literature Review of Advanced Non-Small Cell Lung Cancer trials Research Report on Advanced Non-Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tucatinib Continuation Study tucatinib - HER2-positive Breast Cancer, Cervical Cancer | Phase 4 | Not yet recruiting | Pfizer | 175 | 2026-11-06 | 2026-08-28 |
| A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors [68Ga]Ga-DWJ155 - Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer | Phase 1 | Recruiting | Novartis Pharmaceuticals | 66 | 2026-09-08 | 2026-10-13 |
| HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01) Cyclophosphamide, Fludarabine, IL-2 (interleukin 2) - Advanced Non-Small Cell Lung Cancer | Phase 1 | Recruiting | Hangzhou Huasai Biomedicine Co., Ltd. | 12 | 2026-08-30 | 2026-10-14 |
| A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) Tislelizumab - Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | Recruiting | BeOne Medicines | 440 | 2026-06-05 | 2026-10-15 | |
| Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy Non-Small Cell Carcinoma of Lung, Immunotherapy | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 600 | 2026-05-01 | 2026-06-25 | |
| Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer Lorlatinib - Advanced Non-Small Cell Lung Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-04-24 | 2026-10-13 |
| Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC Circulating Tumor-Specific T Cell Nanodetection Technology (CTT-NanoDT) - Non-Small Cell Lung Cancer, Lung Adenocarcinoma | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 80 | 2026-04-01 | 2026-02-06 | |
| Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer PF-08634404, Pembrolizumab, Chemotherapy Regimen 1 - Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Pfizer | 1410 | 2026-01-06 | 2026-10-08 |
| A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors PF-08046876, Pembrolizumab, Cisplatin - Advanced/Metastatic Solid Tumors, Bladder Cancer | Phase 1 | Recruiting | Pfizer | 540 | 2025-08-20 | 2026-10-13 |
| SSGJ-707 in Advanced Non-Small Cell Lung Cancer SSGJ-707, Pembrolizumab - Advanced Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | 420 | 2025-06-20 | 2025-06-24 |
| Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC JSKN016, Carboplatin, Furmonertinib Mesylate - Advanced Non-small Cell Lung Cancer | Phase 1 | Recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 288 | 2025-04-02 | 2026-03-30 |
| Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function HS-10241 - Advanced Non-small Cell Lung Cancer | Phase 1 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 32 | 2025-02-28 | 2025-02-12 |
| Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) Reduced Dose of Chemotherapy and Immunotherapy - Non-Small Cell Lung Cancer, NSCLC | Phase 2 | Recruiting | Virginia Commonwealth University | 40 | 2025-02-11 | 2026-06-02 |
| Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study JSKN016, Docetaxel - Advanced Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 220 | 2025-01-17 | 2025-01-15 |
| Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC SHR-A1921；Adebrelimab；SHR-8068；carboplatin - Advanced Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-10-10 | 2026-04-08 | |
| Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers TQB2928 injection + Almonertinib Mesilate Tablets - Advanced Non-small Cell Lung Cancer | Phase 1 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 20 | 2024-09-01 | 2024-09-05 |
| A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants BAY2927088, Midazolam - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Completed | Bayer | 15 | 2024-04-17 | 2024-07-03 |
| A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants BAY2927088, Itraconazole, Carbamazepine - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Completed | Bayer | 30 | 2024-04-10 | 2024-06-20 |
| A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants BAY2927088, Esomeprazole, Food - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Completed | Bayer | 21 | 2024-03-29 | 2024-07-05 |
| A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants BAY2927088, Dabigatran etexilate, Rosuvastatin - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Completed | Bayer | 15 | 2024-03-25 | 2024-07-05 |
Showing 20 of 89. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (22) · Lung Neoplasms (7) · Adenocarcinoma (2) · Adenocarcinoma Of Esophagus (2) · Adenocarcinoma of Lung (2) · Carcinoma, Transitional Cell (2) · Head and Neck Neoplasms (2) · Melanoma (2) · Neoplasm Metastasis (2) · Small Cell Lung Carcinoma (2) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Adenosquamous (1) · Carcinoma, Renal Cell (1)
Neoplasms (28) · Neoplasms by Site (27) · Lung Diseases (25) · Respiratory Tract Diseases (25) · Respiratory Tract Neoplasms (25) · Thoracic Neoplasms (25) · Bronchial Neoplasms (24) · Carcinoma, Bronchogenic (24) · Lung Neoplasms (18) · Neoplasms by Histologic Type (8) · Neoplasms, Glandular and Epithelial (7) · Carcinoma (6) · Adenocarcinoma (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3)
Docetaxel (10) · Carboplatin (8) · pembrolizumab (7) · Cisplatin (6) · Pemetrexed (6) · Gemcitabine (5) · Bevacizumab (3) · Nivolumab (3) · Paclitaxel (3) · S 1 (combination) (3) · Vinorelbine (3) · aflutinib (3) · cemiplimab (3) · Cetuximab (2) · Cyclophosphamide (2)
Bayer (7) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd (4) · National Cancer Institute, Naples (4) · Pfizer (4) · Regeneron Pharmaceuticals (3) · ArriVent BioPharma, Inc. (2) · Hunan Province Tumor Hospital (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Novartis Pharmaceuticals (2) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · Taiho Oncology, Inc. (2) · Affiliated Cancer Hospital & Institute of Guangzhou Medical University (1) · Akeso (1) · BeOne Medicines (1) · Beijing Biostar Pharmaceuticals Co., Ltd. (1)
China (33) · United States (30) · Spain (13) · Italy (12) · South Korea (12) · Canada (11) · Taiwan (11) · France (10) · United Kingdom (10) · Australia (9) · Japan (9) · Netherlands (7) · Poland (6) · Germany (5) · Israel (5)
Cesare Gridelli, M.D. (4) · Ciro Gallo, M.D., Ph.D. (2) · Fabio Benedetti, MD (2) · Francesco Perrone, M.D., Ph.D (2) · Francesco Perrone, M.D., Ph.D. (2) · Andrea Ardizzoni, MD (1) · Arielle Elkrief, MD (1) · Caicun Zhou, MD,PhD (1) · Charles Butts, M.D. (1) · Ciro Gallo, M.D., Ph.D (1) · Daichi Fujimoto, MD (1)
PMID 25624439, PMID 17513173, PMID 18632181, PMID 19380175, PMID 22778317, PMID 23109689, PMID 23154555, PMID 24353914, PMID 25371077, PMID 26291008, PMID 27052652, PMID 30264504, PMID 30714987, PMID 31954624, PMID 32094063, PMID 32121014, PMID 32245160, PMID 33322522, PMID 34048946, PMID 35810553, PMID 37185961, PMID 37429923, PMID 37754485, PMID 38601485, PMID 38684230, PMID 39004647, PMID 40020696, PMID 41104928
2023 (3), 2025 (3), 2004 (1), 2005 (1), 2016 (1), 2017 (1), P30CA072720 (1), P50CA196530 (1)